Several dysfunctions may affect the brain, leading to a huge burden on individuals and on society, with 260 million European citizens having some form of brain diseases. Among the most frequent is Alzheimer’s Disease (AD). AD only is predicted to affect 14 million Europeans by 2040 with a cost of about EUR 140 billion in care per year. Brain research is a particularly difficult challenge, involving a multidisciplinary approach for understanding pathophysiologic mechanisms. A gap in the clinics needs to be filled by proposing new imaging agents for early and specific recognition of Alzheimer’s disease (AD) before clinical presentation. Specific peptides are envisaged, as are nanotechnologies. I2PAD objective is to develop theranostic probes for the early detection of AD by molecular imaging-for stratification of patients and then for personalized medicine. I2PAD will combine in the same tool (i) specific vectors of AD with (ii) true theranostic radionuclides (44/43/47Sc, 64/67Cu) for early diagnostics, prognostic prediction, and then adapted therapies to each patient. Our end‐product is the delivery of a suitable radiopharmaceutical for further translation into the clinics for improved management of AD patients (from TRL 3 to TRL 5).